KRROKorro Bio, Inc.
Pharmaceutical Preparations
- Revenue
- $6M
- 181% YoY
- Operating margin
- -1906.4%
- 53% YoY
- EBITDA
- −$118M
- 33% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$25M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired120% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $14M | $0 | $0 | $2M | $6M | 181% |
| Operating income | −$84M | −$59M | −$85M | −$92M | −$122M | 33% |
| Net income | −$85M | −$58M | −$81M | −$84M | −$117M | 40% |
| Operating cash flow | −$76M | −$54M | −$67M | −$60M | −$79M | 31% |
| Capex | $3M | $5M | $8M | $18M | $518K | 97% |
| Stock-based comp | $22M | $20M | $2M | $4M | $8M | 72% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $15M · 10
- Open-market sells, 12 mo
- $786K · 7
- Net
- $14M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 4 | — |
| FY2024 | — | — | 20 | — |
| FY2023 | — | — | 25 | — |